Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LOWER RESPIRATORY TRACT INFECTIONS IN ELDERLY PATIENTS WITH ASTHMA

Alan J. Hunter, MD, and Richard E. Bryant, MD

Infection plays a significant role in the morbidity and mortality of the elderly. One population in which infection has not been adequately studied is the elderly asthmatic. This article examines the problems of lower respiratory tract infections in elderly asthmatics in the context of their host defenses, the severity of infection, and their risk of infection with specific organisms. The role of infection in the pathogenesis of asthma and consideration of prophylaxis and therapy are presented.

DEMOGRAPHICS

Bronchial asthma is not generally considered to be a disease of the elderly. Population surveys, however, show that the prevalence of asthma in the elderly ranges from 2.4% to 12.2%. In a study comparing late-onset asthma and long-standing disease in nonsmoking elderly asthmatics, Braman et al noted that 48% of patients developed asthma after 65 years of age. In a review of 10 population studies, Enright et al found the prevalence of asthma to range from 2.4% to 6.6%. Banerjee et al noted that 61% of randomly selected geriatric day-hospital patients exhibited airflow obstruction on pulmonary function testing. Of those with airflow obstruction 41.2% demonstrated greater than 15% improvement in peak expiratory flow rate following inhalation...
of 200 µg of salmeterol. In addition to chronic asthma, the incidence of new cases after 60 years of age appears to remain relatively constant, ranging from two to six cases per thousand. Advances in technology, nutrition, and medicine have set the stage for profound increases in the geriatric populations, such that the over-85 age group is the fastest growing segment of society in North America. Based on current trends, by the year 2020, the over-65 and over-75 age groups will constitute 22% and 14.2% of the populations in the industrialized nations. Thus we can anticipate a sustained increase in geriatric asthmatics requiring care. The principles of managing asthma in elderly patients differ little from those of treating younger patients. The impaired excretion of drugs by the kidney and liver, however, and greater likelihood of comorbid diseases and adverse drug–drug interactions make the management of asthma in elderly patients complex.

Infection-related mortality in the elderly is three- to 20-fold higher for given diseases compared with younger patients. Pneumonia-associated mortality in the elderly ranges from 5.9% to 32.9%, accounting for 89% of all pneumonia and influenza deaths in the United States between 1979 and 1992, and with influenza is the fifth leading cause of death in patients over 65 years of age. A recent 2-year prospective observational study of independent elderly individuals reported that 54% of those older than 65 years of age had respiratory tract infections, of which bronchitis, pneumonia, and influenza constituted 42% of the total respiratory infections. The severity of lower respiratory tract infections is a function of host susceptibility, the virulence of the infecting agent, and the extent of disease at the start of therapy.

HOST DEFENSES

Normal Lung Defenses

Resistance to microbial invasion of the lower respiratory tract is multifactorial and complex. The respiratory tract immune system is composed of both specific and nonspecific defense mechanisms that consist of a variety of anatomic, neurologic, cellular, and humoral mechanisms. The integrity of these mechanisms, pathogen virulence and the size of the bacterial inoculum play key roles in colonization and subsequent infection of the lower respiratory tract. A variety of conditions contributing to alveolar fluid accumulation place the host at an increased risk of pneumonia. Diminishing host defenses increase the vulnerability of elderly asthmatic patients to more protracted and debilitating consequences of lung infections. Increased vulnerability may also reflect the increased prevalence of diseases associated with fluid retention, such as cardiac, renal, or liver failure, swallowing disorders, altered consciousness, deconditioning due to a sedentary lifestyle, or adverse effects of malnutrition, immunosuppression, or malignancy. Harford and Hara
demonstrated the harmful effects of increased lung water on the survival of mice with experimental pneumonia. A 15-fold increase in mortality was described in mice inoculated with endobronchial bacteria, following endobronchial infusion of saline or serum. Effective phagocytosis cannot occur under these conditions in the absence of opsonic antibodies. Disease-related pulmonary dysfunctions associated with an increased frequency of lower respiratory tract infection are as follows:

**Disorders of Swallowing or Coughing**
- Advanced age, debilitation, trauma, surgery
- Altered consciousness, seizure disorder
- Neurologic or neuromuscular disorder (esophageal disorders)
- Severe underlying disease

**Disorders of Mucociliary Defenses**
- Chronic bronchitis, bronchiectasis, viral infection, ciliary-dysfunction syndromes
- Exposure to irritants, alcohol, anesthesia, cold

**Alveolar Fluid Accumulation**
- Burns, trauma, acute respiratory distress syndrome
- Congestive heart failure, nephrosis, cirrhosis
- Viral, mycoplasmal, or bacterial infection

**Altered Alveolar Macrophage Function**
- Irritants, viral infection, uremia

**Impaired Phagocytosis or Bacterial Clearance**
- Asplenic or dysplenic states
- Comorbid disease (acquired immunodeficiency syndrome, diabetes mellitus, hypogammaglobulinemia, sickle cell disease, malnutrition, immunosuppression)

**The Immunosenesence of Aging**

The immune decline of elderly patients is best considered an immunosenesence as opposed to an immunodeficiency state. Numerous age-related in vitro immune deficiencies have been demonstrated in the elderly:

**Structural/Neurologic Deficiencies**
- Homogeneous increase in air spaces
- Loss of airway elastic recoil
- Impairments of cough reflex
- Decreased mucociliary clearance

**B-Cell Deficiencies**
- Decreased immunoglobulin production
- Decreased antibody binding avidity
- Increased circulating autoantibodies
- Increased incidence of benign monoclonal gammopathies (BMG)
- Association of BMG with multiple myeloma, amyloidosis, malignant lymphoproliferative processes
T-Cell Deficiencies

**Proliferative responses**
- Decreased mitogenic response to plant lectins
- Decreased mixed lymphocytic response
- Decreased proliferative response to OKT3 stimulation
- Fewer responsive T cells
- Responsive T cells fail to divide normally when stimulated

**Cytokine/receptor expression**
- Decreased response to interleukin (IL)-2
- Decreased IL-2 production
- Decreased expression of IL-2 receptors
- Decreased production of T-cell growth factors
- Decreased response to T-cell growth factors

**Thymic involution**

Yet despite their acceptance and teleologic attractiveness, these deficiencies' causal relationships to clinical infections are unclear. Chandra noted that in previously healthy individuals, the presence of anergy, lymphopenia, or both was associated with 1-year survival rates of 72%, 58%, and 45%, respectively. In a 16-year longitudinal study of healthy elderly men, decreased absolute lymphocyte counts were noted within 3 years of death. The leukopenia, however, was not age dependent and in both of these studies might have served as a marker of more severe comorbid disease(s). In predominately healthy patients with a mean age of 82 years, a normal inflammatory response to pneumonia was noted, as measured by appropriate rise in C-reactive protein, leukocytosis, and a neutrophil degranulation product, plasma neutrophil elastase α-1-antiproteinase complex. In addition, despite having measurably lower numbers of cytotoxic T lymphocytes at baseline, elderly patients were able to mount an adequate response following inactivated influenza A virus vaccination. These results support the notion that the healthy elderly are still able to mount an adequate immune response to pneumonia. Nasopharyngeal colonization with gram-negative bacteria has been reported to increase in elderly patients, but few studies have looked at the elderly living independently within the community. It is likely that the high rates of colonization are more representative of comorbid illnesses and therapy, in addition to the milieu in which these patients reside. The elderly have an increased incidence of bacteremia, urinary tract infection, diverticulitis, pneumonia, infective endocarditis, disseminated fungal infection, and reactivation of tuberculosis. Although immune dysfunction probably plays a role in these infections, the increased susceptibility of the elderly to infection may in part represent a synergistic effect of comorbid illnesses, nutritional status, and age-dependent organ dysfunction.

**Nutrition In the Elderly**

Saltzman and Peterson noted a 41% to 85% prevalence of protein-calorie malnutrition while reviewing immunodeficiency in the elderly.
Impaired T-cell responsiveness and anergy are known immunologic sequelae of malnutrition and may contribute to the immune dysfunction of the elderly. The provision of nutritional, vitamin, and trace element supplementation for 8 weeks resulted in improved skin test response, increased T-lymphocyte numbers, and responses to mitogen. Zinc may be especially important. Animal studies involving zinc-deficient mice have demonstrated reversible thymic involution and T-cell dysfunction with adequate zinc replacement. These studies have relevance in the elderly because the prevalence of deficient zinc intake and measurable zinc deficiency are 24% and 14%, respectively. In a randomized controlled trial in institutionalized elderly, the administration of 220 mg of zinc sulfate twice daily resulted in increased numbers of circulating T lymphocytes, enhanced delayed cutaneous hypersensitivity, and immunoglobulin G response to tetanus vaccine. Four randomized, double-blind, placebo-controlled trials involving zinc administration for the common cold have demonstrated a decrease in symptoms when compared with placebo. Four additional randomized controlled trials failed to document any clinical improvement with administration of zinc gluconate for the common cold, and in addition found no change in viral shedding. There are numerous proposed mechanisms by which zinc might exert some antimicrobial action, but its clinical role has yet to be worked out. The precise role of vitamin replacement is not established, but clearly adequate caloric and nutritional support are important in the elderly.

Asthma and the Host Immune System

Chronic obstructive lung disease is a predisposing factor for pneumonia in the elderly, but asthma is not generally considered a significant independent risk. Koivula et al, however, in a population-based study of individuals more than 60 years of age in Finland, noted the prevalence of asthma to be 3.5%. When compared with those patients who did not develop pneumonia, the adjusted relative risk for contracting pneumonia in asthmatics was 4.2 (95% confidence interval [CI], range 3.3-5.4), suggesting that asthma itself may predispose patients to develop infection. The presence of lung disease and bronchial asthma did not increase the risk of death. Postulated mechanisms by which asthma causes host immune system dysfunction have been reviewed (Table 1). In addition, mucociliary transport may be slowed by as much as 72% during an acute exacerbation. Multiple authors have described impaired mucociliary transport in asthmatic patients. In addition, hypogammaglobulinemia was 4.8 times more likely to be identified in unselected asthmatics than in the normal population. Of note, 10 of the 12 patients with hypogammaglobulinemia received a cumulative prednisone dose (or its equivalent) of ≥ 5 mg/day for at least 2 years. Because asthma in the elderly is less likely to be responsive to conservative therapy, more elderly asthmatics
Table 1. POSTULATED IMMUNE IMPAIRMENTS ASSOCIATED WITH ASTHMA

| Derangement                                          | Reference(s) |
|-----------------------------------------------------|--------------|
| Viral induced nasociliary dysfunction               | 27           |
| Impaired bronchial mucosal permeability             | 117          |
| Hypogammaglobulinemia                               | 85           |
| Impaired surfactant production                      | 98           |
| Increased antibody catabolism                       | 148          |
| Alteration in adhesion molecule function            | 84           |
| Deficient production of interferon-α                | 96           |
| Impaired mucociliary clearance                      | 10, 25, 97, 106, 117, 149 |

Adapted from Drach FS, Bryant RE: Spotting the pneumococci in today's pneumonia milieu. J Respir Dis(14)2:198-216, 1993; with permission.

will be at risk of suffering the combined immune-altering effects of age, comorbidity, and immunosuppression. In a survey of consecutive geriatric asthmatic patients in their pulmonary practice, Braman et al noted that 22 of 25 patients more than 70 years of age required oral steroids in addition to inhaled corticosteroids, highlighting the potential clinical significance of iatrogenic immune deficiencies. The previously described immune host defense dysfunction may be significant, but may be less important than the combined effects of comorbid disease(s). Asthmatic patients more than 65 years of age have been shown to have six- to 10-fold higher mortality than younger patients, partially attributable to complicating illnesses and therapies, but in addition attributable to delays in presentation, increased noncompliance with medications, poor nutrition, and isolated living situations that predispose them to poorer outcomes.

PNEUMONIA IN ELDERLY ASTHMATICS

The Effects of Age

The separate effects of age and comorbid disease on the susceptibility of the elderly to infection are complex. Many studies have attempted to identify historical, clinical, and laboratory parameters by which physicians could appropriately stratify patients with pneumonia with respect to their need for hospitalization and intensive care. Farr et al reviewed prognostic factors obtained by history that have been associated with death from pneumonia, and they identified 18 studies that showed an association between older age and death. Nine of the studies found an association using univariate analysis, and two studies found an association using multivariate analysis. In a recent study evaluating the utility of radiographic presentation of community-acquired pneumonia, the overall mortality rate of patients 65 years of age or older was 10.2% as compared with the 1.8% mortality rate of patients 45 to 64 years of age, further highlighting the risk of age and infection. In a metaanalysis, Fine et al noted 14 cohort studies that evaluated the
association of age and mortality, with a mean age difference in survivors versus nonsurvivors of 7.8 years. In the same study, logistic regression analysis performed on 85 cases noted an odds ratio of 1.05 (95% CI, range 1.01-1.09) of death for each 10-year increment in mean patient age. Although this metaanalysis found age to be significantly associated with death, the weight of comorbid illness was not addressed. Studies by Esposito et al, Black et al, and Lipsky et al, which corrected for comorbid factors, found that age was not a significant risk factor for mortality. Using retrospectively derived prognostic parameters, Black et al noted that ambulatory elderly patients were more likely to be admitted with pneumonia than younger patients. When a multivariate analysis was performed controlling for comorbid conditions, age was no longer predictive. In a retrospective case control study, Lipsky et al noted dementia, seizure disorders, and institutionalization to be associated with acquiring pneumococcal infections. In the same study, age was not significantly associated with pneumococcal pneumonia when corrected for comorbidities. These observations support the overriding importance of an individual's physiologic status as a determinant for initiating invasive life-saving medical therapy.

The Effect Of Asthma

The precise relationships between infection and asthma are unclear. As previously mentioned, Koivula et al showed that elderly asthmatics have an increased risk of pneumonia when compared with the general age-matched population, suggesting that asthma per se may predispose elderly patients to pneumonia. Although this is a tenable hypothesis it is unclear whether comorbid illness or therapy with corticosteroids might have prevented detection of the separate effects of asthma as a risk factor for pneumonia. More extensive work has gone into trying to elucidate the mechanism by which infections may affect the risk of or perpetuate the course of asthma. Similarly it is not totally clear whether asthmatic patients have a different incidence or worsened prognosis with viral, bacterial, or combined infection.

Many studies have evaluated the role of preceding viral infection in the development of airway hyperresponsiveness in children. The role of infection in the pathogenesis of asthma and its exacerbations in adults continues to be controversial. Few studies have separated bronchial asthma from chronic obstructive pulmonary disease, hence there are few if any clinical data demonstrating whether asthma predisposes one to develop respiratory tract infections. In the only study addressing bronchial asthma as an independent comorbidity, Koivula et al noted bronchial asthma to be second only to alcoholism as a risk for pneumonia. This study, involving elderly independent Finns, showed that asthmatics had an adjusted relative risk for pneumonia and hospitalization of 4.2 (95% CI, range 3.3-5.4) and 6.0 (95% CI, range 4.1-9.0), respectively, when compared with the remainder of the population. This
increased risk remained statistically significant after a multivariate analysis for all significant comorbidities. There is a need for further studies in this area.

**Bacterial Infections and Asthma**

Bacterial infections have a minimal or inapparent role in asthma exacerbations except for the recently described association of *Chlamydia pneumoniae* and the development of asthma. In a study involving young asthmatics, McIntosh et al. found no difference in the bacterial isolation rates of pneumococcus, *Hemophilus influenzae*, β-hemolytic streptococci, *Staphylococci aureus*, or enteric bacteria when looking at symptomatic versus asymptomatic asthmatics. Several studies have suggested a possible role of *Mycoplasma pneumoniae* in the development of asthma exacerbations. In a study involving 77 wheezing asthmatics, from 8 months to 31 years of age, Gil et al. were able to isolate *M. pneumoniae* in 24.7% of subjects compared with 5.7% of controls. Several studies have associated *Mycoplasma* sp with asthma, but its clinical importance is still uncertain. In a study in adults, Hudgel et al. confirmed these results, finding no difference in bacterial isolation rates when comparing symptomatic versus asymptomatic asthmatics. In addition, Berman et al. using transtracheal biopsy, did not correlate bacterial isolation with exacerbations when comparing symptomatic versus asymptomatic asthmatics. Studies looking at antimicrobial therapy for acute exacerbations of asthma have found no difference in outcomes between those who received antibiotics and controls. Exclusive of secondarily infected upper respiratory infection, bacterial infection appears to play a minimal role in asthma exacerbations and therefore antimicrobials are seldom indicated.

**Chlamydia Pneumoniae and Asthma**

*C. pneumoniae* causes a number of respiratory and nonrespiratory inflammatory conditions. The seroprevalence in the population ranges from 30% to 50%, with about 50% positivity in older patients. In a prospective study involving 365 Wisconsin outpatients, Hahn et al. assessed the association of *C. pneumoniae* infection with wheezing, asthmatic bronchitis, and adult-onset asthma. In the prospective phase, three (11%) of 27 patients with pneumonia and 16 (4.7%) of patients with bronchitis had positive serology for *C. pneumoniae*. Of these 19 infected patients, three (16%) had wheezing with their acute infection, and six (32%) developed bronchospasm during the ensuing 6 months. After controlling for confounding variables, a *C. pneumoniae* titer of 1:16 or more was associated with an odds ratio of 2.1 (95% CI, range 1.1–4.2) for developing wheezing. In the matched control phase of the study, 29.6% of *C. pneumoniae*-positive patients compared with 7% of controls were diagnosed with asthma, with an odds ratio of 7.2 (95% CI, range
2.2–23.4). This finding was further substantiated by demonstrating a dose–response relationship between titers and the presence of wheezing. *C. pneumoniae* titers of 1:16 and 1:128 or more were associated with odds ratios for wheezing of 1.2 (not significant) and 3.5 (significant), respectively. Eighty percent of patients diagnosed with asthma following their illness had a *C. pneumoniae* titer of more than or equal to 1:64, and of these six (75%) developed chronic asthma following bronchitis, and one (12.5%) following pneumonia. Asthmatic bronchitis was more likely to occur in older reinfected patients, raising the question whether *C. pneumoniae* might have exerted an immune-mediated effect on the lung.73, 80

In a follow-up study composed of asthmatics with and without chronic obstructive pulmonary disease (COPD), Hahn and Golubjatnikov81 reported 100% *C. pneumoniae* seroreactivity in asthmatics, 80% seroreactivity in asthmatic bronchitis patients without antecedent asthma, and 52.8% seroreactivity in patients with nonwheezing respiratory illness. Additional studies have had similar results associating *C. pneumoniae* with asthma.5, 79–81, 150 A recent community-based open-label treatment trial involving asthmatic patients with a mean *C. pneumoniae* titer of 1:128 showed significant improvement in 54% of patients after 4 weeks of varying antimicrobial treatments (doxycycline, azithromycin, or erythromycin), as reflected by improvement in forced expiratory volume in 1 second (FEV1) and symptoms.79 Nonresponders were more likely to be receiving inhaled corticosteroids, to have a lower mean FEV1/forced vital capacity (FVC) ratio at baseline, and to have a significantly longer history of asthma symptoms prior to treatment. This is an interesting study, but it is hampered by the lack of a control arm and the association of significant impairment of pulmonary function tests prior to testing in the nonresponder arm. Grayston74 found the incidence of wheezing and asthma to be no higher in *C. pneumoniae* than *M. pneumoniae* or viral respiratory disease (respiratory syncytial virus [RSV], influenza A and B, and adenovirus). This recent recognition of the association of *C. pneumoniae* with asthma is yet another linkage of infection to an inflammatory condition. The exact implications of the *Chlamydia*-asthma association are yet to be defined and further study is needed to characterize improved diagnostic and therapeutic options available to clinicians.

**Viral Infection and Airway Hyperresponsiveness**

In children, viral respiratory tract infections have been shown to play a significant role in the development of acute asthma, as well as contributing to the pathogenesis of airway hyperresponsiveness. Epidemiologic studies in children have established a convincing link between antecedent viral respiratory tract infection and acute asthma exacerbations, and as potential causative agent in the pathogenic process of airway hyperresponsiveness.118, 172 Table 2 summarizes proposed patho-
Table 2. PROPOSED MECHANISMS OF VIRAL-INDUCED AIRWAY HYPERREACTIVITY

| Mechanism                                           | Reference@) |
|-----------------------------------------------------|--------------|
| Immunoglobulin E-mediated mast cell sensitization   | 65, 174      |
| Induction of atopy                                   | 192          |
| Enhanced leukocyte histamine release                 | 24, 95       |
| Diminished p-adrenergic function                     | 179          |
| Enhanced cholinergic-dependent bronchospasm         | 44, 159      |
| Epithelial injury                                   | 113, 117, 159|
| Enhanced T-cell activation                          | 68, 192      |

Adapted from Gyetko MR, Toew GB: Immunology of the aging lung. Clin Chest Med 14:379–391, 1993; with permission.

genic mechanisms by which viral infections exacerbate pre-existing asthma, as well as cause airway hyperreactivity. Viral infections have been shown to decrease peak flow rates\(^{75, 171}\) and induce airway epithelial damage, thereby potentially increasing antigenic exposure in the host,\(^{115, 117, 159}\) which may result in increased airway reactivity in normal or genetically predisposed hosts.\(^{75, 82, 116}\) Viral infections and influenza vaccination have been shown to cause nonspecific bronchial hyperresponsiveness in asthmatics.\(^{99, 133}\) Hence, although clinical and experimental evidence support a causal link between neonatal and childhood RSV infections and bronchiolitis, and subsequent asthma, there is conflicting evidence that this occurs in adults.\(^{118, 172, 175, 177, 180}\)

Epidemiologic studies have addressed the possible role of viral infection in asthma exacerbations. Pattemore et al.\(^{146}\) reviewed the epidemiology of viral illness and asthma and noted four studies in children that identified significantly elevated virus isolation rates in symptomatic asthmatics, compared with asymptomatic asthmatics.\(^{91, 93, 100, 132}\) Rhinoviruses have been associated with the majority of cases of virus-mediated infective asthma, with RSV, parainfluenza, adenovirus, influenza virus, and coronavirus comprising the remainder.\(^{11, 101, 135, 146}\) Lemanske et al.\(^{116}\) induced rhinovirus infections in 10 adults allergic to ragweed, noting increased airway reactivity to both allergen and histamine provocation. In addition, eight of 10 patients experienced a greater than 15% decline in FEV\(_1\) within 6 hours of the antigen challenge. In a longitudinal study of adult asthmatics 19 to 46 years of age, Nicholson et al.\(^{141}\) identified nonbacterial pathogens in 44% of asthma exacerbations associated with cold symptoms. Twenty-four percent of laboratory-confirmed infections were associated with significant airflow obstruction. In this study, viral pathogens accounted for 93% of all infections, of which rhinovirus and coronavirus accounted for the majority. In children identification rates during exacerbation have approached 20% to 60%.\(^{26, 91, 100, 129, 131}\) Viral respiratory tract infections are likely to play a role in adult exacerbations but to a lesser extent. Viral identification rates during exacerbation in adults range between 10% and 19%.\(^{11, 93, 94, 146}\) Minor et al.\(^{131}\) and Hudgel et al.\(^{193}\) noted that viral isolation rates in adults were significantly lower than rates in children (10% to 13% versus 40% to 60%).\(^{95, 94, 129}\) In a small
prospective study involving adult asthmatics 15 to 59 years of age, Beasley et al. reported an overall viral isolation rate of 10%, which increased to 36% in association with severe asthma exacerbations (FEV₁ < 60% or peak expiratory flow rate < 40%). Sixty percent of viral respiratory tract infections were associated with an acute asthma exacerbation. In a study of 253 exacerbations in 67 asthmatics, Kava found that 25% of asthma exacerbations were associated with symptomatic respiratory tract infections, and 55% of respiratory tract infections were associated with an asthma exacerbation. In the same study, viral-associated asthma exacerbations had a more protracted course than did exacerbations unassociated with a viral illness, or an uncomplicated viral respiratory tract infection: 11.4 days versus 8.1 days versus 4.9 days, respectively. Although the isolation rates in adults are significantly lower than those in children, these studies support the notion that viruses contribute to exacerbation of bronchial hyperreactivity in adults as well as children.

All studies have not reported an association between antecedent viral infections and asthma. Tarlo et al. isolated virus in only 3% of adults with asthma exacerbations presenting with symptoms of an upper respiratory tract infection, a rate identical to the isolation rate of asymptomatic individuals. Similarly, Sokhandan et al. obtained nasal swabs for viral isolation from 33 of 35 adults during asthma exacerbations that necessitated emergency room evaluation. In total, 55.9% of patients had symptoms consistent with an upper respiratory tract infection, yet by immunofluorescence, culture, or complement fixation testing, none of these had evidence of viral infection. Sokhandan and coworkers rationalized that despite expecting a higher isolation rate in emergency room presentations, as compared with the rates noted in ambulatory clinics, this lower rate raised significant questions about the role of viral infections in adult asthma exacerbations. Hence, there are solid yet conflicting data concerning viral-mediated exacerbation of asthma in adults, with little specific data in the elderly.

Aspergillus In Elderly Asthmatics

Aspergillus can affect the asthmatic host by several pathologic mechanisms. It may cause a profound allergic reaction in atopic individuals with preexisting bronchial asthma, it may coexist by colonizing the respiratory mucosa, or it may progress to more severe invasive aspergillosis. Allergic bronchopulmonary aspergillosis (ABPA) is the most common allergic bronchopulmonary mycosis. It is characterized by fever, malaise, sputum production with brown mucous plugs, pulmonary eosinophilia, a significant allergic response in the bronchi and skin, and proximal bronchiectasis, in the setting of established asthma or another chronic lung disease such as cystic fibrosis. The clinical course varies from mild asthma exacerbations to severe pulmonary fibrosis following years of repeated inflammatory episodes. In 1952, Hinson et al. first described ABPA syndrome in three patients with
recurrent asthma, peripheral eosinophilia, fever, sputum production, and abnormal chest radiographs. Aspergillus fumigatus later grew out of sputum culture. This association of A. fumigatus and ABPA has subsequently been well documented. Although A. fumigatus is responsible for the majority of cases, the syndrome may occasionally be caused by other Aspergillus spp, as well as other fungi. Additional diagnostic considerations for A. fumigatus-negative patients with a compatible clinical syndrome are Pseudoallescheria boydii, Candida albicans, Curvularia lunata, Rhizopus spp., Helminthosporium spp, Penicillium spp, Stemphylium spp, Torulopsis glabrata, Bipolaris spp, hawaiiensis, and Fusarium vasinfec-

tum. No formal studies have evaluated the prevalence of ABPA in the elderly. In a recent study of asthmatics preselected for having positive immediate A. fumigatus skin tests, however, 28% of patients fulfilled clinical criteria for ABPA. Of these episodes, 36% had proximal bronchiectasis on radiographic interpretation. In this study, the over-60 age group accounted for 24% of the study population, yet was responsible for 39% of ABPA diagnoses. In addition, 46% of the over-60 patients had a diagnosis of ABPA during the study, compared with only 18% of patients younger than 60 years of age. This preliminary information highlights the potential clinical significance of ABPA in the elderly population, hence enforcing our need to consider ABPA in patient evaluation.

Summary

In summary, infection clearly has a significant role in asthma. Although the evidence linking viral infection to asthma exacerbations and pathogenesis is convincing in children, it is less convincing in adults. The epidemiologic studies reviewed did not focus on the elderly population, hence we are required to extrapolate the above association of virus-mediated airway hyperresponsiveness in children and younger adults to consideration of the elderly patient. This area needs more work. At one time bacterial infections were considered a likely cause of asthmatic exacerbations; however, except for the recently proposed association of C. pneumoniae and asthma, and to a lesser degree M. pneumoniae, bacteria are considered to play a minor role in recurrent episodes of airway hyperresponsiveness in children and adults alike. Methodologic limitations of easily identifying infective agents causing lower respiratory tract infections severely limits progress in this area.

Perhaps the most important insight into the role of prior respiratory viral infection in secondary bronchial reactivity is provided by study of prior viral infections in patients with sinusitis or otitis media. The very elegant studies available from the examination of cultures, antigen detection, or serologic confirmation of middle ear or sinus aspiration specimens have shown a clear association between primary viral and secondary bacterial infection of the sinuses or middle ear. Unlike the normally sterile milieu of the sinuses and middle ear, the lower
respiratory tract lies distal to the heavily colonized oropharynx, thus impairing more precise microbiologic assessment.\textsuperscript{16, 47} Clarification of the exact relationship between viral, bacterial, or combined infection in the asthmatic awaits a better assessment of microbial infection that can bypass contamination from the oropharynx. Considering the multitude of infectious agents and the expense and methodologic complexity of defining infections of the nose, oropharynx, lung, and gastrointestinal tract, it is amazing that we know as much as we do.

**MANAGEMENT OF INFECTION**

**Prevention and Prophylaxis**

Waning immunity is cited as a potentially correctable host defense defect in the elderly.\textsuperscript{109} Despite the availability of vaccines for viral influenza, and \textit{Streptococcus pneumoniae}, these important protective measures are often omitted. The viral influenza vaccine should be given each year in the late fall. The pneumococcal vaccine is especially important because it protects against invasive pneumococcal infection and its current formulation includes antigens from multidrug-resistant strains that would be more difficult to treat with antibiotics. Unfortunately, severely ill patients, those with comorbid diseases, and the immunocompromised elderly are substantially less likely to respond to this or other vaccines. Pneumococcal immunization is usually given at or about 65 years of age, but it should be given at a younger age to patients with cardiac, pulmonary, renal, or hepatic disease that would increase their susceptibility to invasive pneumococcal disease.\textsuperscript{35, 138, 139} There is controversy over the desirability of repeated vaccination. Dermal reactivity to reimmunization is seldom a problem in those more than 65 years of age, however, and the elderly without comorbid disease show no statistical impairment of immunologic responsiveness to the vaccine.\textsuperscript{139, 140} Five-year efficacy in immunocompetent 65- to 74-year-olds was 71\% and in 75- to 84-year-olds was 67\%.\textsuperscript{107} Considering that data and conceding that definitive studies with elderly asthmatics are unlikely to become available, it seems prudent to provide pneumococcal immunization to elderly asthmatic patients on the basis of their other underlying disease(s) (i.e., cardiovascular disorders, chronic pulmonary diseases, renal failure, alcoholism, or hematopoietic malignancies), to begin before 65 years of age in the most vulnerable patients with comorbid disease, and to consider repeating immunization at approximately 5- to 7-year intervals. Better vaccines and better instruments for testing their efficacy in the elderly are needed.

If elderly patients with asthma are at greater risk of serious sequelae from viral infections then measures likely to reduce the risk of viral infection should be beneficial.\textsuperscript{108} Societal practices also contribute to enhanced respiratory infection in the elderly. Vulnerable patients are
grouped together in nursing homes and often subjected to affectionate and effusive reunions with families, children, grandchildren, and other carriers of infectious microbes that can then be circulated rapidly among the susceptible residents. Adults have approximately four viral infections per year and children average six to eight per year; thus, it is wise for grandparents and great-grandparents to avoid contact with children likely to have active viral infection, a logical but often unacceptable choice. Rhinoviral illness is often transmitted by infectious nasopharyngeal secretions and, therefore, is potentially amenable to reduction by barrier precautions, frequent hand washing, and returning babies to their parents if they need attention for their runny noses.

The lay press has suggested that improved handwashing practices in nursery schools can reduce colds in the home by nearly 50%. This thesis is given credibility by studies documenting the transmissibility of viruses on fomites and the hands of volunteers, the frequency with which children and adults pick their noses or rub their eyes, and the infectivity of viruses inoculated onto the nasal mucosa or conjunctiva. Thus appropriate attention to handwashing, disposal of soiled tissues, and interruption of the transmission of infected nasopharyngeal secretions should benefit the elderly. The common sense benefits from covering the mouth during a cough were recognized to reduce risks of transmission of tuberculosis in the 1960s and are also applicable to reduce transmission of certain viral infections. We need to document and expand our repertoire of ways of interrupting transmission of viral infections to our elderly and infirm patients. Risks of respiratory infection can also be associated with vocational or recreational exposures. Geographic and exposure risk factors associated with respiratory disease that are not host-specific for asthmatic patients are shown in Table 3.

It seems prudent to advise physicians caring for vulnerable elderly asthmatics to help prevent fluid retention secondary to cardiac, renal, or liver failure. Those at risk of aspiration due to hiatal herniae, gastroesophageal reflux, or presbyesophageal or other swallowing disorders should have thoughtful evaluation and advice as to precautions for eating, sleeping, and safe swallowing techniques.

Table 3. ENVIRONMENTAL AND ZOONOTIC EXPOSURES

| Exposure                                                                 | Pathogen                          |
|------------------------------------------------------------------------|-----------------------------------|
| Birds (farm, pets, wild, tame, domestic, foreign)                       | Chlamydia psittaci                 |
| Parturient animals (sheep, goats, cows, cats)                          | Coxiella burnetii                  |
| Cave exploration, chicken or starling roosts, excavation in histoplasmosis areas | Histoplasma capsulatum            |
| Dust storms or ground exposure in coccidioidomycosis areas             | Coccidioides immitis               |
| Ground squirrels, rodents, or burrows in Southwestern US desert        | Yersinia pestis                    |
| Contaminated water and plumbing                                        | Legionella pneumophila             |
Diagnostic Assessment

As discussed previously, asthmatic patients with respiratory disease usually have asthma that is not linked to bacterial infection and is not helped by antibiotics. Sputum purulence can be associated with eosinophil-rich exudates or with viral infection that confounds diagnostic assessment. Likewise, criteria for assessing the severity and need for hospitalization for an asthma attack are well defined and distinct from diagnostic assessment and criteria for hospitalization for pneumonia. This article addresses issues relevant to lower respiratory tract infection in elderly patients who happen to have asthma. In most instances concomitant asthma will have little effect on the most common bacterial causes of pneumonia in that group. In rare instances protracted therapy with high doses of corticosteroids may reactivate tuberculosis or opportunistic fungal or nocardia infections. Likewise Pneumocystis carinii infection can complicate high-dose corticosteroid therapy in relatively normal hosts. It is well to keep these situations in mind, but they are extremely rare (Table 4).

Diagnosis of respiratory infection in the elderly is based on the statistical probability of a specific infection considering host vulnerability, epidemiologic risks, and clinical presentation. Therapy is based on the clinical clues, laboratory evaluation, and the assessment of the severity of the patient’s illness.

The cause of community-acquired pneumonia varies with the patient’s age, comorbid disease, disability, and exposure to infectious agents. Pneumonia is generally attributed to S. pneumoniae (20% to 60%), H. influenzae (3% to 10%), gram-negative bacilli (3% to 10%), S. aureus (3% to 5%), legionella (2% to 8%), C. pneumoniae (4% to 6%), viral pneumonia (2% to 15%), and aspiration (6% to 10%).9 51 112 126 The cause of pneumonia is unknown in 20% to 30% of patients and the frequency of combined infection is probably higher than recognized. Kauppinen and coworkers suggested mixed infection may occur in more than a third of patients hospitalized with C. pneumoniae.104 Lieberman and coworkers119 reported age-specific etiologic data for pneumonia. Patients

| Organism                  | Reference(s) |
|---------------------------|---------------|
| Aspergillus pneumonia     | 35, 156       |
| Candida spp               | 156           |
| Cytomegalovirus           | 156           |
| Invasive aspergillosis    | 145, 194      |
| Legionella spp            | 1             |
| Mucormycosis              | 176           |
| Pneumocystis carinii      | 1, 157, 165   |
| Strongyloides stercoralis | 102           |
| Tuberculosis              | 166, 191      |
| Varicella pneumonia       | 32, 136, 191  |
more than 65 years of age had pneumococcal pneumonia (46% to 57%),
*H. influenzae* (4%), *M. pneumoniae* (4% to 13%), legionella (8% to 15%),
and *C. pneumoniae* (24% to 28%). The latter statistic is comparable to
figures cited by Grayston, who noted an increased incidence of *C. pneumoniae* in the elderly. This finding has special relevance to the
erly asthmatic patient, who might be expected to have a higher
likelihood of worsening asthma and a more prolonged illness after a *C. pneumoniae* infection.

**Criteria For Hospitalization**

There have been a series of elegant studies documenting risk factors
associated with severe pneumonia and a bad prognosis. The
features of the history, physical examination, or laboratory assessment
associated with severe pneumonia that requires hospitalization and often
admission to an intensive care unit are as follows:

**History**

- Age more than 65 years
- Comorbidity (COPD, diabetes mellitus, malignancy, immunode-
  ficiency, fluid retention from heart, liver, or renal disease)
- Hospitalization within prior year
- Postsplenectomy
- Chronic alcoholism, malnutrition, immunosuppression

**Physical Examination**

- Respiration more than 30 breaths per minute
- Shock (blood pressure ≤ 90/60 mm Hg)
- Temperature greater than 101°F
- Altered consciousness or confusion
- Extrapulmonary signs of disease; meningitis, endocarditis, arthritis

**Laboratory Findings**

- White blood cell count less than 4000/mm³ or more than 30,000/
  mm³; more than 5% bands
- Significant elevation in bands
- PaO₂ ≤ 60 mm Hg or PaCO₂ ≥ 50 mm Hg on room air
- Elevated creatinine or BUN
- Hematocrit less than 30%, Hgb less than 9 g/dL
- Acidosis, disseminated intravascular coagulation, prolonged pro-
  thrombin time or partial thromboplastin time, thrombocytopenia
- Lobar pneumonia, multiple lobe pneumonia, cavitation, effusions,
  empyema, or rapid radiographic progression
- *S. aureus*, gram-negative bacilli, aspiration, or polymicrobial origin

Labored breathing, inability to mobilize secretions, and a rapidly pro-
gressive course necessitate evaluation for intubation and ventilatory
assistance. Sicker and more vulnerable patients require more aggressive
diagnostic work-up, including bronchoscopy, aspiration of parapneumonic effusions, and monitored assessment in an intensive care unit. A clinical prediction rule for 30-day mortality in patients with community-acquired pneumonia has recently been studied. A weighted point system, based on the number of adverse indicators, can be applied to calculate the patient’s mortality risk. This work is a significant advance and provides an improved structure for testing treatment decisions in patients with pneumonia.

Additional contributions have been made regarding indicators of mild disease that permit ambulatory treatment of patients with pneumonia. Criteria supporting the appropriateness of outpatient therapy include youth, lack of comorbid diseases, and absence of features indicating severe infection or an especially virulent pathogen:

**Normal Host**
- Age less than 50 years who can and will take medication dependably (and will communicate if disease worsens)
- Lacks host defense defects associated with cardiac, renal, or liver failure, cerebrovascular disease, debility due to malignancy, chronic lung disease, immunosuppression, or nursing home residence

**Objective Features Suggesting Mild Disease**

**Historical and Physical Findings**
- Nonprogressive clinical course
- Normotensive, normothermic, alert, and oriented patient with normal respiratory rate, pulse less than 125, and no signs of extrapulmonic sepsis

**Laboratory Findings**
- Normal oxygenation, acid–base balance and hemoglobin levels
- Postintervention PEFR or FEV1 greater than 50% of baseline values
- Normal platelet, white blood cell, and differential leukocyte count
- Normal renal function and coagulation values
- Minimal bronchopneumonia without pleural effusion, cavitation, or empyema
- Probability of low-risk pathogens

The authors emphasized that clinical judgment should supersede their guidelines and that broader applications await further testing. Interestingly, bronchial asthma was not associated with an adverse prognosis.

Suggestions for antimicrobial therapy of patients requiring hospitalization for community-acquired pneumonia have been nicely summarized by the recent works of the American Thoracic Society and Bartlett and Mundy. Empiric therapy of elderly patients requiring hospitalization for pneumonia usually includes cephalosporins to treat pneumococcal or *Hemophilus* strains, and macrolides with or without rifampin for Legionella. Patients at risk of gram-negative bacillary, staphylococcal, or aspiration pneumonia are treated with regimens shown in Table 5.
### Table 5. RECOMMENDED TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN THE ELDERLY

| Suspected Pathogen                     | First Choice                                      | Alternatives                                                                 |
|----------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------|
| **Streptococcus pneumoniae**           | Ceftriaxone/Cefotaxime†                            | Vancomycin                                                                   |
|                                        |                                                   | Macrolides‡                                                                   |
|                                        |                                                   | Cefuroxime                                                                   |
|                                        |                                                   | β-lactamase inhibitor combinations§                                          |
|                                        |                                                   | Parenteral fluoroquinolones§                                                 |
|                                        |                                                   | Azithromycin                                                                  |
| **Hemophilus influenzae**              | Ceftriaxone/Cefotaxime†                            |                                                                              |
|                                        |                                                   |                                                                              |
| **Aerobic gram-negative bacilli**      | Cephalosporins as above with or without aminoglycoside‖                          |                                                                              |
|                                        |                                                   |                                                                              |
| **Staphylococcus aureus**              | Nafcillin                                         |                                                                              |
|                                        |                                                   | Cefazolin/Cefuroxime                                                         |
|                                        |                                                   | Vancomycin for methicillin-resistant Staphylococcus aureus                    |
| **Polymicrobial anaerobic**            | Clindamycin plus cefotaxime                       | β-lactamase inhibitor combinations§                                          |
| **Legionella pneumophila**             | Parenteral erythromycin-azithromycin†‡‡‖¹⁰,1²²      | Rifampin                                                                      |
| **(rare)**                             |                                                   | Parenteral fluoroquinolones                                                  |
| **Mycoplasma pneumoniae**              | Macrolides†¹¹⁰                                   | Doxycycline                                                                   |
| **(rare)**                             |                                                   | Levofloxacin***                                                              |
| **Chlamydia pneumoniae**               | Macrolides†¹¹⁰                                   | Doxycycline                                                                   |
| **Chlamydia psittaci or Coxiella burnetii** | Doxycycline                                         | Azithromycin                                                                  |
|                                        |                                                   | Levofloxacin***                                                              |

*Hypotensive or critically ill patients should also receive vancomycin.
*Severely ill patients require broader coverage according to risk of specific diseases. Similarly, patients with risk of multiple pathogens like legionella, mycoplasma, or *C. pneumoniae* plus concomitant bacterial disease will require erythromycin, another macrolide, doxycycline, or a parenteral fluoroquinolone in addition to specific coverage for *S. pneumoniae* or other bacteria likely to be present. Anti-pneumococcal coverage is always necessary because of the frequency of pneumococcal pneumonia. Multi-drug-resistant pneumococcal pneumonia can probably be treated adequately with high-dose cephalosporins but patients at risk of concomitant endocarditis, meningitis, or endophthalmitis may require concomitant parenteral vancomycin, meropenem, or rifampin.
†Erythromycin, azithromycin, or clarithromycin.
‡β-lactamase inhibitor combination: ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin-tazobactam.
§Parenteral fluoroquinolones: ciprofloxacin, levofloxacin, Trovofloxacin.
‖Aminoglycoside or parenteral fluoroquinolone is added to ceftriaxone or cefotaxime.
††Imipenem or meropenem is indicated for severely ill immunocompromised patients with risk of nosocomial infection.
**Patients with comorbid disease are diagnosed and treated according to risks of specific diseases or complications of organ failure. Patients with AIDS, neutropenia, and leukemia or organ transplants require evaluation for opportunistic infections. Severely ill patients require more invasive diagnostic studies.
†††Patients with gram-negative bacillary pneumonia caused by *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Enterobacter* or *Serratia* spp should receive two antibiotics effective against the suspected pathogen (usually a β-lactam plus an aminoglycoside or parenteral ciprofloxacin (depending on renal dysfunction or prior antibiotic therapy).
‡‡‡Patients with organ failure or shock should receive two agents effective against the primary pathogen plus therapy for intracellular pathogens like *Legionella* spp, *M. pneumoniae*, or *C. pneumoniae*.
§§Victor Yu, MD, personal communication, April 1997.
‖‖Patients with pneumonia and prominent wheezing or exacerbations of asthma during infection should have treatment that includes coverage for *C. pneumoniae* while that diagnosis is being confirmed.
¶¶Young, overtly healthy patients with minimal bronchopneumonia infiltrates and no indicators of serious disease can be treated with macrolides as outpatients.
***Only to be used in the elderly, nonmenstruating patient.
Hypotensive patients with organ failure or fulminant infection receive broadly based empiric therapy until diagnostic studies permit institution of pathogen-specific therapy. Patients with multidrug-resistant pathogens are an increasing problem; their therapy must be individualized. Of equal importance is the rapidly progressive pneumonia that may occur with bacteremia or with infection caused by *S. pyogenes*, plague, primary viral influenza, or staphylococcal pneumonia complicating viral influenza. Primary fungal pneumonia with blastomycosis, histoplasmosis, coccidioidomycosis, or cryptococcosis rarely causes fulminant infection. Perhaps the most common fulminant pneumonia in the elderly is bacteremic pneumococcal pneumonia, which may present abruptly with shock in the absence of cough or sputum production.

**Inpatient Management**

Penicillin-resistant pneumococcal infection has become a widespread problem in the United States. In many areas of the country, 20% to 30% of strains will have intermediate to high-level resistance to penicillin and, therefore, penicillin is no longer the drug of choice for the primary treatment of suspected pneumococcal pneumonia. Pneumococcal pneumonia caused by strains with intermediate penicillin sensitivities of 0.1 to less than 1.0 μg/mL can be treated with cephalosporins like ceftriaxone (1 to 2 g/day), or cefotaxime (3 to 6 g/day). Patients with meningitis or fulminant pneumococcal infection should be treated with vancomycin plus cefotaxime or ceftriaxone until sensitivity data become available. It is important to remember that ceftizoxime is 10- to 100-fold less active than cefotaxime or ceftriaxone against penicillin-resistant pneumococci. It has been suggested that cefotaxime dosage can be increased to 12 to 24 g daily to treat critically ill patients with marginally sensitive pneumococci. The applicability of this approach requires further study.

**Outpatient Management**

Elderly asthmatic patients with pneumonia are usually hospitalized because they are at greater risk of serious infection. The need for admission is based on the evidence of the severity of their infectious disease, and the severity of their asthma. Patients who are overtly well, who have indicators of mild disease, and who are clinically stable, however, may be treated as outpatients and followed carefully. Although an algorithmic approach to triaging the elderly patient may give a sense of false security, the “healthy” elderly patient with posttreatment FEV₁ or peak expiratory flow rate (PEFR) greater than 60% of previous best or of predicted may be considered for outpatient management. Eligibility for ambulatory care requires a cooperative and dependable patient with an adequate support system to verify that the patient is taking and
retaining medicines (i.e., not vomiting them up) and responding to ambulatory antibiotic therapy.

Oral antibiotics for the elderly asthmatic patient with pneumonia must provide adequate coverage for \textit{S. pneumoniae} and \textit{H. influenzae}.

Broader-spectrum oral antibiotics like ampicillin-clavulanate, cefuroxime, or azithromycin meet this need. Alternative combination therapy with 1 g of parenteral ceftaxetine and oral macrolide therapy provides substantial coverage until the patient's course and treatment can be reviewed the next day. Although oral fluoroquinolone treatment of pneumococcal pneumonia has been considered controversial in the past, the newer agent levofloxacin may be an acceptable alternative as experience is gained with its use. \textit{M. pneumoniae} or \textit{C. pneumoniae} can be treated with macrolides, doxycycline, or the fluoroquinolones cited previously.

Atypical pneumonia in the elderly asthmatic patient is less likely to be due to \textit{M. pneumoniae}, but is often caused by \textit{C. pneumoniae}. The latter infection may exacerbate prior respiratory disease in the asthmatic patient or cause pneumonia presenting with new-onset asthma. The disease usually moves slowly through family members, causing complaints of pharyngitis, sinusitis, dry and poorly productive cough, headache, and malaise. The disease may cause a persistent illness with chronic circulating immune complexes that enhance atherosclerotic disease in elderly patients. While the magnitude and frequency of that phenomena are being clarified scientifically, it seems prudent to initiate therapy early in the course of illness because of the potential benefits of shortening the duration of infection, ameliorating effects of asthma, and reducing risk of vascular disease.

Uncomplicated pneumonia caused by \textit{S. pneumoniae}, \textit{H. influenzae}, or \textit{M. pneumoniae} usually can be treated adequately in 7 to 10 days. \textit{C. pneumoniae} generally is treated for 5 days with azithromycin or 10 to 14 days with other agents. Legionella pneumonia in the compromised patient may require 21 days of treatment.

There has been some concern over the use of fluoroquinolones as primary treatment of respiratory tract disease. Fluoroquinolones are contraindicated in pregnancy and therefore should not be used in sexually active women whose risk of pregnancy is uncertain. Ciprofloxacin is known to impair clearance of theophylline and can only be used with close monitoring of theophylline blood level, and sparfloxacin has an increased risk of photosensitivity. Levofloxacin and sparfloxacin do not affect theophylline metabolism but greater experience is required to demonstrate their efficacy as alternatives to parenteral therapy for elderly asthmatics with pneumonia.

The new fluoroquinolones are less active than ciprofloxacin against \textit{Pseudomonas aeruginosa} and most fastidious gram-negative aerobic bacilli. Ciprofloxacin is the fluoroquinolone of choice against these pathogens and is used in conjunction with another effective parenteral agent in hospitalized patients. As a class, the fluoroquinolones lack dependable efficacy against \textit{Stenotrophomonas} and \textit{Nocardia} spp. The fluoroquinolones
have no antiviral or antifungal activity and should not be used as single-drug therapy for mycobacterial infection. The place of the new fluoroquinolones for treatment of polymicrobial anaerobic infection or fulminant pneumonia is not established. The breadth of the spectrum of activity of the fluoroquinolones has been responsible for their widespread misuse. Enthusiasm for their use has obscured the fact that their overuse increases the risk of emergence of fluoroquinolone resistance, thereby jeopardizing the future of even better fluoroquinolones currently under development.

We need to reiterate the importance of defining the most likely microbial cause(s) of pneumonia prior to selecting an antibiotic to eradicate the pathogen causing infection. Focusing on the patient’s risk of infection and the pathogen(s) causing it makes it easier to identify appropriate diagnostic studies and to remain alert to errors of diagnosis and treatment.

Therapy of Viral Infection

Viral respiratory diseases of elderly asthmatic patients are essentially the same as those of other patients of comparable age or debility. Illness from viral influenza A can be ameliorated by early treatment with either amantadine or rimantidine. Amantadine is primarily excreted by the kidneys, so the dose should be adjusted to reflect reduced renal function in the elderly. The ordinary amantadine dose of 100 mg twice daily is usually adjusted to 100 mg daily in the elderly or renally impaired patient. Rimantidine is excreted primarily by the liver, so its dosage need not be adjusted for renal dysfunction.

Patients with fulminant influenza A, influenza B, or respiratory syncytial viral (RSV) infection have been successfully treated with inhalational ribavirin. This experience has been largely limited to severely ill patients requiring ventilatory assistance in an intensive care unit or patients with unusually severe host defense defects owing to liver, lung, or bone marrow transplantation, women in the third trimester of pregnancy, and a few very sick patients with ostensibly normal host defenses. The experience of RSV pneumonia in bone marrow transplant recipients suggests that treatment within the first 4 days of illness, prior to onset of clear-cut respiratory insufficiency, is required to modify the nearly 100% mortality seen in such patients. Treatment can be given as an 18-hour inhalation procedure or as a higher-dose treatment given four times daily. Current experience suggests that concomitant intravenous gamma globulin administration is helpful in bone marrow transplant patients with RSV pneumonia. Although elderly patients are known to be at increased risk of severe RSV, influenza A, or influenza B infection, most elderly patients with those infections will go undiagnosed, and will not receive ribavirin therapy. Ribavirin therapy should be thought of as a potentially useful therapeutic alternative.
for critically ill elderly patients whose course suggests RSV or influenza A or B infection.

Likewise, patients with primary herpes simplex, pneumonia, chickenpox pneumonia, or cytomegaloviral pneumonia can benefit from appropriate antiviral therapy with acyclovir, gancyclovir, or foscarnate. These illnesses are rare in the elderly asthmatic patient but need to be considered in the context of concomitant illness such as leukemia, lymphoma, and acquired immunodeficiency syndrome.¹³, ¹⁹

**Therapy for Fungal-Mediated Hypersensitivity**

ABPA may occur as a complication of asthma or cystic fibrosis. Patients usually require protracted therapy with prednisone, and their disease often relapses when the prednisone dose is reduced. Treatment with antifungal agents has been limited by the inability of current antimicrobials to eradicate aspergillus from bronchopulmonary tissues. At least three nonrandomized studies, however, have demonstrated a benefit from oral itraconazole therapy coupled with steroid therapy,⁶⁷, ¹⁴ as reflected by reduction in serum immunoglobulin E, eosinophilia, and improvement in FEV₁ during therapy with itraconazole.⁵⁸, ¹²⁴ These studies support an adjunctive role for itraconazole that may permit reduction, or rarely cessation, of prednisone ABPA therapy. Controlled trials are needed to document the validity of this contention. Likewise, evaluation of newer, more potent therapy for aspergillus pulmonary infection is badly needed.

**CONCLUSION**

In conclusion, asthma is underrecognized in the geriatric population and has some special considerations. Although data are lacking in the elderly, epidemiologic studies in younger age groups strongly suggest the causative and provocative roles of infection in asthma. Future evaluation must be performed to better characterize what role viral and bacterial infections have in the geriatric population. As the role of *C. pneumoniae* and other infections in asthma is better defined, more specific therapy may be possible. The normal lung defense mechanisms decline with age, but clinical disease and therapeutic strategies are more dependent on organ dysfunction and underlying comorbid diseases. Thus assessment and specific therapy are dependent on an individual's physiologic health rather than chronologic age. For now, selection of therapy should be based on host vulnerability, the epidemiologic risk of infection, the severity of the patient's infection, and the virulence of potential pathogens. Although conceding the importance of antimicrobial therapy once infection occurs, one must continue to stress the importance of good hygiene, adequate nutrition, proper surveillance of the patient's
asthma, and more vigilant use of vaccines to prevent infection in asthmatic patients.

References

1. Abernathy-Carver KJ, Fan LL, Boguniewicz M, et al: Legionella and Pneumocystis pneumonia in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 18:135–138, 1994

2. Abramson JS, Giebink GS, Quie PG: Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect Immun 36:289–296, 1989

3. Al-Nakib W, Higgins PG, Barrow I, et al: Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 20:893–901, 1987

4. Albazzaz MK, Pal C, Berman P, et al: Inflammatory markers of lower respiratory tract infection in elderly people. Age Ageing 23:299–302, 1994

5. Allegra L, Blasi F, Centanni S, et al: Acute exacerbations of asthma in adults: Role of Chlamydia pneumoniae in infection. Eur Respir J 7:2165–2168, 1994

6. Appelbaum PC: Epidemiology and in vitro susceptibility of drug-resistant streptococcus pneumoniae. Pediatr Infect Dis J 15:932–939, 1996

7. Backman KS, Roberts M, Patterson R: Allergic bronchopulmonary mycosis caused by Fusarium vasinfectum. Am J Respir Crit Care Med 152:1379–1381, 1995

8. Banerjee DK, Lee GS, Malik SK, et al: Underdiagnosis of asthma in the elderly. Br J Dis Chest 81:23–29, 1987

9. Bartlett JG, Mundy LM: Community-acquired pneumonia. N Engl J Med 333:1618–1624, 1995

10. Bateman JR, Pavia D, Sheahan NF, et al: Impaired tracheobronchial clearance in patients with mild stable asthma. Thorax 38:463–467, 1983

11. Beasley R, Coleman ED, Hermon Y, et al: Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax 43:679–683, 1988

12. Bender BS, Nagel JE, Adler WH, et al: Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. J Am Geriatr Soc 34:649–654, 1986

13. Berkovich S, Millian SJ, Snyder RD: The association of viral and mycoplasma infections with recurrence of wheezing in the asthmatic child. Ann Allergy 28:43–49, 1970

14. Berman SZ, Mathison DA, Stevenson DD, et al: Transtracheal aspiration studies in asthmatic patients in relapse with “infective” asthma and in subjects without respiratory disease. J Allergy Clin Immunol 56:206–214, 1975

15. Beveridge RC, Grunfeld AF, Hodder RV, et al: Guidelines for the emergency management of asthma in adults. Can Med Assoc J 155:25–37, 1996

16. Bjuggren G, Kraepelien S, Lind J: Sinusitis in children at home and in day-nurseries. Ann Paediatr 173:205–221, 1949

17. Black ER, Mushlin AI, Griner PF, et al: Predicting the need for hospitalization of ambulatory patients with pneumonia. J Gen Intern Med 6:394–400, 1991

18. Braman SS: Asthma in the elderly patient. Clin Chest Med 14:413–422, 1993

19. Braman SS, Kaemmerlen JT, Davis SM: Asthma in the elderly: A comparison between patients with recently acquired and long-standing disease. Am Rev Respir Dis 143:336, 1991

20. British Thoracic Society and the Public Health Laboratory Service: Community-acquired pneumonia in adults in British hospitals in 1982–1983: A survey of aetiology, mortality, prognostic factors and outcome. QJM 62:195–220, 1987

21. Broder I, Higgins MW, Mathews KP, et al: Epidemiology of asthma and allergic rhinitis in a total community, Tecumseh, Michigan: III. Second survey of the community. J Allergy Clin Immunol 53:127, 1974

22. Broder I, Higgins MW, Mathews KP, et al: Epidemiology of asthma and allergic rhinitis in a total community, Tecumseh, Michigan: IV. Natural History. J Allergy Clin Immunol 54:100, 1974
23. Bryant RE: Viral pneumonia. In Braude A, Davis C, Flere J (eds): Infectious Disease and Microbiology, ed 2. Philadelphia, WB Saunders Co, 1986

24. Busse WW, Swenson CA, Borden EC, et al: Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol 71:382-388, 1983

25. Cammer P, Jarstrand C, Philipson K: Transbronchial clearance in patients with influenza. Am Rev Respir Dis 108:131-135, 1973

26. Carlsson KH, Ørstavik I, Leegaard J, et al: Respiratory virus infections and aeroallergens in acute bronchial asthma. Arch Dis Child 59:310-315, 1984

27. Carson JL, Collier AM, Hu SS, et al: Acquired ciliary defects in the nasal epithelium of children with acute viral upper respiratory tract infections. N Engl J Med 312:463-468, 1985

28. Cassel CK: In Cassel CK, Cohen HJ, Larson EB, et al: Geriatric Medicine, ed 3. New York, Springer-Verlag, 1997, pp xi-xiii

29. Centers for Disease Control: Pneumonia and influenza death rates—United States, 1979-1994. MMWR Morb Mortal Wkly Rep 44:535-537, 1995

30. Chandra RK: Nutritional regulation of immunity and risk of infection in old age. Immunology 67:141-147, 1989

31. Chandra RK, Joshi P, Au B, et al: Nutrition and immunocompetence of the elderly. Effect of short-term nutritional supplementation on cell-mediated immunity and lymphocyte subsets. Nutr Res 2:223-232, 1982

32. Choong K, Zwaigenbaum L, Onyett H: Severe varicella after low dose inhaled corticosteroids. Pediatr Infect Dis J 14:809-811, 1995

33. Cimolai N, Wensley D, Sear M, et al: Mycoplasma as a cofactor in severe respiratory infections. Clin Infect Dis 21:1182-1185, 1995

34. Connolly MJ, Crawley JJ, Charan NB, et al: Reduced subjective awareness of bronchocstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 47:410-413, 1992

35. Crean JM, Niederman MS, Fein AM, et al: Rapidly progressive respiratory failure due to Aspergillus pneumonia: A complication of short-term corticosteroid therapy. Crit Care Med 20:148-150, 1992

36. Crossley KB, Peterson PK: Infections in the elderly. In Mandell GL, Bennet JE, Dolin R (eds): Principles and Practices of Infectious Diseases, ed 4. New York, Churchill-Livingstone, 1995, pp 2737-2742

37. Daley J, Jencks S, Draper D, et al: Predicting hospital-associated mortality for medicare patients: A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. JAMA 260:3617-3624, 1988

38. Denning DS, VanWyke JD, Lewiston NJ, et al: Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 100:813-819, 1991

39. Dodge RR, Burrows B: The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 122:567-575, 1980

40. Douglas RM, Miles HM, Moore BW, et al: Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infection in Australian adults. Antimicrob Agents Chemother 31:1263-1265, 1987

41. Drach FS, Bryant RE: Spotting the pneumococcus in today's pneumonia milieu. J Respir Dis 14:198-216, 1993

42. Duchateau J, Delepesse G, Vrijens R, et al: Beneficial effects of oral zinc supplementation on immune response of old people. Am J Med 70:1001-1004, 1981

43. Eby GA, Davis DR, Hakcomb WW: Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 23:20-24, 1984

44. Empey DW, Laitinen LA, Jacobs L, et al: Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infections. Am Rev Respir Dis 113:131-139, 1976

45. Enright PL, Kronmal RA, Higgins MW, et al: Prevalence and correlates of respiratory symptoms and disease in the elderly. Chest 106:827-834, 1994

46. Esposito AL: Community-acquired bacteremic pneumococcal pneumonia: Effect of age on manifestations and outcome. Arch Intern Med 144:945-948, 1984
LOWER RESPIRATORY TRACT INFECTIONS IN ELDERLY PATIENTS WITH ASTHMA

47. Evans FO Jr, Sydnor JB, Moore WEC, et al: Sinusitis of the maxillary antrum. N Engl J Med 293:735–739, 1975
48. Evans R, Mullally DL, Wilson RW, et al: National trends in the morbidity and mortality of asthma in the US. Chest 91:655–74S, 1987
49. Falsey AR, Cunningham CK, Barker WH, et al: Respiratory syncytial virus and influenza A infections in hospitalized elderly. J Infect Dis 172:389–394, 1995
50. Falsey AR, McCann RM, Hall WJ, et al: Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 43:30–36, 1995
51. Fang G, Fine MJ, Orloff J, et al: New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 69:307–316, 1990
52. Farr BM: Prognosis and decisions in pneumonia. N Engl J Med 336:288–289, 1997
53. Farr BM, Conner EM, Betts RF, et al: Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother 31:1183–1187, 1987
54. Farr BM, Sloman AJ, Fisch MJ: Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 115:428–436, 1991
55. Fedson DS, Shapiro ED, LaForce FM, et al: Pneumococcal vaccine after 15 years of use: Another view. Arch Intern Med 154:2531–2535, 1994
56. Fernandes C, Nair M, Onoe K, et al: Improvement of cell-mediated immunity functions by dietary zinc deficiency in mice. Proc Natl Acad Sci USA 76:457–461, 1979
57. File TM, Segreti J, Dunbar L, et al: A multicenter randomized study comparing the efficacy and safety of IV/PO levofloxacin vs ceftriaxone/cefuroxime axetil in the treatment of adults with community acquired pneumonia [abstract]. Am Soc Microbiol 1:280, 1996
58. Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 336:243–250, 1997
59. Fine MJ, Hough IJ, Medsger AR, et al: The hospital admission decision for patients with community-acquired pneumonia: Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 157:36–44, 1997
60. Fine MJ, Singer DE, Hanusa BH, et al: Validation of a pneumonia prognostic index using the MedisGroups comparative hospital database. Am J Med 94:153–159, 1993
61. Fine MJ, Smith DN, Singer DE: Hospitalization decision in patients with community-acquired pneumonia: A prospective cohort study. Am J Med 89:713–721, 1990
62. Fine MJ, Smith MA, Carson CA, et al: Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 274:134–141, 1996
63. Fink MP, Snyderman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter randomized double blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 38:547–557, 1994
64. Fraker PJ, DePasquale-Jardieu P, Zwicky CM, et al: Regeneration of T cell helper function in zinc deficient adult mice. Proc Natl Acad Sci USA 75:5660–5664, 1978
65. Frick OL, German DF, Mills J: Development of allergy in children. I. Association with virus infections. J Allergy Clin Immunol 63:228–241, 1979
66. Furner SE, Brody JA, Jankowski LM: Epidemiology and aging. In Cassel CK, Cohen HJ, Larson EB, et al: Geriatric Medicine, ed 3. New York, Springer-Verlag, 1997, pp 37–43
67. Germaud P, Tuchats E: Allergic bronchopulmonary aspergillosis treated with itraconazole. Chest 107:883, 1995
68. Gem JC, Vetis R, Kelly EA, et al: Rhinovirus produces non-specific activation of lymphocytes through a monocyte dependent mechanism. J Immunol 157:1605–1612, 1996
69. Giebink GS: The microbiology of otitis media. Pediatr Infect Dis J 8:S18–S20, 1989
70. Gil JC, Cedillo RL, Mayagotia BG, et al: Isolation of Mycoplasma pneumoniae from asthmatic patients. Ann Allergy 70:23–25, 1993
71. Godfrey JC, Conant-Sloane B, Smith DS, et al: Zinc gluconate and the common cold: A controlled clinical study. J Intern Med Res 20:234–246, 1992
72. Granton JT, Grossman RF: Community-acquired pneumonia in the elderly patient. Clin Chest Med 14:537–553, 1993
73. Grayston JT: Chlamydia pneumoniae, strain TWAR. Chest 95:664–669, 1989
74. Grayston JT: Chlamydia pneumoniae (TWAR). In Mandell GL, Bennet JE, Dolin R (eds): Principles and Practices of Infectious Diseases, ed 4. New York, Churchill-Livingstone, 1995, p 1698
75. Gregg I: Provocation of airflow limitation by viral infection: Implication for treatment. Eur J Respir Dis (suppl)369–379, 1983
76. Gwaltney JM: Acute community-acquired sinusitis. Clin Infect Dis 23:1209–1225, 1996
77. Gyetko MR, Toews GB: Immunology of the aging lung. Clin Chest Med 14:379–391, 1993
78. Haas DW, Stratton CW, Griffin JP, et al: Diminished activity of ceftriaxone against Streptococcus pneumoniae. Clin Infect Dis 20:671–676, 1995
79. Hahn DL: Treatment of Chlamydia pneumoniae infection in adult asthma: A before-after trial. J Fam Pract 41:345–351, 1995
80. Hahn DL, Dodge RW, Golubiatnikov R: Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266:225–230, 1991
81. Hahn DL, Golubiatnikov R: Asthma and Chlamydia infection: A case series. J Fam Pract 38:589–595, 1994
82. Hall WJ, Hall CB, Speers DM: Respiratory syncytial virus infection in adults: Clinical, virologic, and serial pulmonary function studies. Ann Intern Med 88:203–205, 1978
83. Halsey PB, Albbaum MN, Li Y, et al: Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 156:2206–2212, 1996
84. Hamacher J, Schabel T: Adhesion molecules in lung disease [abstract]. Lung 172:189–213, 1994
85. Hamilos DL, Young RM, Peter JB, et al: Hypogammaglobulinemia in asthmatic patients. Ann Allergy 68:472–480, 1992
86. Hamory BH, Sande MA, Sydnor A, et al: Etiology and antimicrobial therapy of acute maxillary sinusitis. J Infect Dis 139:197–202, 1979
87. Harford C, Hara M: Pulmonary edema in influenza pneumonia of the mouse and the relation of fluid in the lung to the inception of pneumococcal pneumonia. J Exp Med 185:225–230, 1950
88. Henderson FW, Collier AM, Sanyal MA, et al: A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 306:1377–1383, 1982
89. Hendley JO, Gwaltney JM Jr: Mechanisms of transmission of rhinovirus infection. Epidemiol Rev 10:242–258, 1988
90. Hinson KFW, Moon AJ, Plummer NS: Bronchopulmonary aspergillosis. Thorax 7:317–333, 1952
91. Horn MEC, Brain EA, Gregg J, et al: Respiratory viral infection and wheezy bronchitis in childhood. Thorax 34:23–28, 1979
92. Horn MEC, Reed SE, Taylor P: Role of viruses and bacteria in acute wheezy bronchitis in childhood: A study of sputum. Arch Dis Child 54:587–592, 1979
93. Hudgel DW, Langston L, Selner JC, et al: Viral and bacterial infections in adults with chronic asthma. Am Rev Respir Dis 120:393–397, 1979
94. Huhti E, Mokka T, Nikoskelainen I, et al: Association of viral and mycoplasma infections with exacerbations of asthma. Ann Allergy 33:145–149, 1974
95. Ida S, Hooks JJ, Siranganian RP, et al: Enhancement of IgE-mediated histamine release from human basophils by viruses. J Exp Med 145:892–896, 1977
96. Isaacs D, Clarke JR, Tyrrell DAJ, et al: Deficiency of production of leukocyte interferon (interferon-α) in vitro and in vivo in children with recurrent respiratory tract infections. Lancet ii:950–952, 1981
97. Jarstrand C, Camner P, Philipson K: Mycoplasma pneumonia and transbronchial clearance. Am Rev Respir Dis 110:415–419, 1974
98. Javorka K, Calkovsk A: The pulmonary surfactant factor. Current knowledge, research trends and use in clinical practice [abstract]. Bratislavske Lokarske Listy 95:452–455, 1994
LOWER RESPIRATORY TRACT INFECTIONS IN ELDERLY PATIENTS WITH ASTHMA

99. Jenkins CR, Breslin ABX: Upper respiratory tract infections and airway reactivity in normal and asthmatic subjects. Am Rev Respir Dis 130:879–883, 1984
100. Jennings LC, Barns G, Dawson KP: The association of viruses with acute asthma. NZ Med J 100:488–490, 1987
101. Johnston S, Pattemore P, Smith S, et al: Viral infections in exacerbations in school-children with cough and wheeze: A longitudinal study. Am Rev Respir Dis 145:A546, 1992
102. Kaslow JE, Novey HS, Zuch RI, et al: Disseminated strongyloidiasis: An unheralded risk of corticosteroid therapy. J Allergy Clin Immunol 86:138, 1990
103. Kauffman HF, Tomee JFC, Van Der Werf TS, et al: Review of fungus-induced asthmatic reactions. Am J Respir Crit Care Med 151:2109–2116, 1995
104. Kauppinen M, Saikko P: Pneumonia due to Chlamydia pneumoniae: Prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 21:244–252, 1995
105. Kava T: Acute respiratory infection, influenza vaccination and airway reactivity in asthma. Eur Respir Dis 150:7–38, 1987
106. Kava T: Effect of respiratory infections on exacerbation of asthma in adult patients. Allergy 41:556–561, 1986
107. Knight V, McClung JW, Wilson SZ, et al: Ribaviran small-particle aerosol treatment of influenza. Lancet 31:945, 1981
108. Koivula I, Sten M, Makela PH: Risk factors in pneumonia in the elderly. Am J Med 96:313–320, 1994
109. Kouradsen HB: Quality and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly patients. Clin Infect Dis 21:616–620, 1995
110. Kuzman I, Soldo I, Schönwald S, et al: Azithromycin for treatment of community-acquired pneumonia caused by legionella pneumophila: A retrospective study. scand J Infect Dis 27:503–505, 1995
111. LaCroix AZ, Lipson S, Miles TP, et al: Prospective study of pneumonia hospitalizations and mortality of U.S. older people: The role of chronic conditions, health behaviour, and nutritional status. Public Health Rep 104:350–360, 1989
112. Laforce MF: Antimicrobial therapy for lower respiratory tract infections in adults: A review. Clin Infect Dis 14(suppl 2):233–237, 1992
113. Laitinen LA, Heino M, Laitinen A, et al: Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 131:599–606, 1985
114. Larson E: A causal link between handwashing and risk of infection. Examination of the evidence. Infect Control Hosp Epidemiol 9:28–36, 1988
115. Leitman PS: Fluoroquinolone toxicities—an update. Drugs 49(suppl 2):159–163, 1995
116. Lemanske RF, Dick EC, Swenson CA, et al: Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 83:1–10, 1989
117. Lemarchand P, Chinet T, Collignon M, et al: Bronchial clearance of DTPA is increased in acute asthma but not in chronic asthma. Am Rev Respir Dis 145:147–152, 1992
118. Li JT, O'Connell EJ: Viral infections and asthma. Ann Allergy 59:321–328, 1987
119. Lieberman D, Schlaffer F, Bolder I, et al: Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 51:179–184, 1996
120. Lipsky BA, Boyko EJ, Inui TS, et al: Risk factors for acquiring pneumococcal infections. Arch Intern Med 146:2179–2185, 1986
121. Little JW, Hall WJ, Douglas RG Jr, et al: Amantadine effect on peripheral airways abnormalities in influenza. A study in 15 students with natural influenza infection. Ann Intern Med 85:117, 1976
122. Lode H, Garau J, Grassi C, et al: Treatment of community-acquired pneumonia: A randomized comparison of spiramycin, amoxycillin-davidamic acid and erythromycin. Eur Respir J 8:1999–2007, 1995
123. Lorber B: The common cold. J Gen Intern Med 11:229–236, 1996
124. Mannes GPM, Van Der Heide S, Van Aalderen WMC, et al: Itraconazole allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis. Lancet 341:492, 1993
125. Marrie TJ, Durant H, Yates L: Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 11:586-599, 1989
126. Marrie TJ: Today's approach to community-acquired pneumonia. J Respir Dis 14:770-780, 1993
127. Mason EO, Lambeth L, Lichenstein R, et al: Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in vitro susceptibilities to selected oral antibiotics. J Antimicrob Chemother 36:1043-1048, 1995
128. McClung HW, Knight V, Gilbert BE, et al: Ribavirin aerosol treatment of influenza B virus infection. JAMA 249:2671, 1983
129. McIntosh K, Ellis EF, Hoffman LS, et al: The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr 82:378-390, 1973
130. Mezey RJ, Cohn MA, Fernandez RJ, et al: Mucociliary transport in allergic patients with antigen-induced bronchospasm. Am Rev Respir Dis 118:677-684, 1978
131. Minor TE, Dick EC, DeMeo AN, et al: Viruses as precipitants of asthmatic attacks in children. JAMA 227:292-298, 1974
132. Mitchell I, Inglis H, Simpson H: Viral infections as a precipitant of wheeze in children: Combined home and hospital study. Arch Dis Child 53:106-111, 1978
133. Moine P, Vercken JB, Chevret S, et al: Severe community-acquired pneumonia: Etiology, epidemiology, and prognosis factors. Chest 105:1487-1495, 1994
134. Monteleone CA, Sherman AR: Nutrition and asthma. Arch Intern Med 137:23-34, 1997
135. Monto AS: Viral respiratory infections in the community: Epidemiology, agents, and interventions. JAMA 227:24-27, 1995
136. Musher DM: Pneumococcal pneumonia: Including diagnosis and therapy of infection caused by penicillin-resistant strains. Clin Infect Dis 15:16-27, 1995
137. Musher DM, Groover JE, Rowland JM, et al: Antibody to capsular polysaccharide of streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 17:66-73, 1993
138. Nicholson KG, Kent J, Ireland DC: Respiratory viruses and exacerbations of asthma in adults. British Medical Journal 307:982-986, 1993
139. Niederman MS, Bass JB, Campbell GD, et al: Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148:1418-1426, 1993
140. Ortqvist A, Sterner G, Nilsson A: Severe community-acquired pneumonia: Factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 17:385-388, 1985
141. Pacheco A, Martin JA, Cuevas M, et al: Serologic response to itraconazole in allergic bronchopulmonary aspergillosis. Chest 103:980-981, 1993
142. Palmer LB, Greenberg SE, Schiff MJ: Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 46:15-20, 1991
143. Pattemore PK, Johnston SL, Bardin PG: Viruses as precipitants of asthma symptoms. Clin Exp Allergy 22:325-336, 1992
144. Patterson R, Samuels BS, Phair JJ, et al: Bronchopulmonary torulopsis. Int Arch Allergy Immunol 69:30-33, 1982
145. Paul S: Catalytic activity of anti-ground state antibodies, antibody subunits, and known autoantibodies [abstract]. Appl Biochem Biotech 47:241-253, 1994
146. Pavia D, Bateman JR, Sheahan NF, et al: Transbronchial mucociliary clearance in asthma: Impairment during remission. Thorax 40:171-175, 1985
147. Peters BS, Thomas B, Marshall B, et al: The role of Chlamydia pneumonia in acute exacerbations in asthma. Am Rev Respir Crit Care Med 149:A341, 1994
151. Petheram IS, Jones DA, Collins JV: Assessment and management of acute asthma in the elderly: A comparison with younger asthmatics. Postgrad Med J 58:149, 1982

152. Powers DC, Belshe RB: Effect of age on cytotoxic T lymphocytes memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 167:584–592, 1993

153. Quelette JJ, Reed CE: Increased response of asthmatic subjects to methacholine after influenza vaccine. J Allergy 36:558–563, 1965

154. Renwick DS, Connolly MJ: Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 51:164–168, 1996

155. Riley RL: Airborne infections. Am J Med 57:466–475, 1974

156. Rodrigues J, Niederman MS, Fein AM, et al: Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med 93:29–34, 1992

157. Roux N, Filpo RM, Cortet B, et al: Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Rev Rheum Engl Ed 63:453–456, 1996

158. Ruben FL, Dearwater SR, Norden CW, et al: Clinical infections in the noninstitutionalized geriatric age group: Methods utilized and incidence of infections. Am J Epidemiol 141:145–157, 1995

159. Saban R, Dick EC, Fishleder RJ, et al: Enhancement by parainfluenza-3 and capsaicin in airway smooth muscle from guinea pig. Am Rev Respir Dis 136:586–589, 1987

160. Saikku P, Leinonen M, Tenkanen L, et al: Chronic Chlamydia pneumoniae infection as a risk factor for coronary artery heart disease in the Helsinki study. Ann Intern Med 116:273–278, 1991

161. Saltzman RL, Peterson PK: Immunodeficiency of the elderly. Rev Infect Dis 9:1127–1139, 1987

162. Sbarbaro JA: Compliance with therapy: How great a problem? J Respir Dis 6:44, 1986

163. Schwartz HJ, Greenberger PA: The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 117:138–142, 1991

164. Seggev JS, Lis I, Siman-Tov R, et al: Mycoplasma pneumoniae is a frequent cause of exacerbation of bronchial asthma in adults. Ann Allergy 57:263–265, 1986

165. Sen RP, Walsh TE, Fisher W, et al: Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 99:143–146, 1991

166. Shaikh WA: Pulmonary tuberculosis in patients treated with inhaled beclomethasone. Allergy 47:327–330, 1992

167. Shapiro ED, Berg AT, Austrian R, et al: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325:1453–1460, 1991

168. Shapiro GG, Eggleston PA, Pierson WE, et al: Double-blind study of the effectiveness of broad spectrum antibiotic in status asthmaticus. Pediatrics 53:867–872, 1974

169. Silva J: Community-acquired pneumonia: It is time for the penicillin bullet to be replaced. Western J Med 164:79–80, 1996

170. Slavin RC, Cannon RF, Friedman WH, et al: Sinusitis and bronchial asthma. J Allergy Clin Immunol 66:250, 1980

171. Slepian IK, Mathews KP, McLean JA: Aspirin-sensitive asthma. Chest 87:386–391, 1985

172. Sly PD, Hibbert ME: Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr Pulmonol 7:153–158, 1989

173. Smith DS, Helzner EC, Nuttall CE Jr, et al: Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 33:646–648, 1989

174. Smith JM: Asthma and atopy as diseases of unknown cause. A viral hypothesis possibly explaining the epidemiologic association of atopic diseases and various forms of asthma. Ann Allergy 72:156–162, 1994

175. Sokhandan M, McFadden ER, Huang YT, et al: The contribution of respiratory viruses to severe exacerbations of asthma in adults. Chest 107(6):1570–1575, 1995

176. Stefanini M, Allegra S: Pulmonary mucormycosis in acute histiocytic leukemia. N Engl J Med 256:1026, 1957

177. Sterk PJ: Virus-induced airway hyperresponsiveness in man. Eur Respir J 6:894–902, 1993
178. Stollerman GH: Infectious diseases. In Cassel, CK, Cohen HJ, Larson EB, et al: Geriatric Medicine, ed 3, New York, Springer-Verlag, 1997, pp 599–626
179. Szentivanyi A: The beta-adrenergic theory of atopic abnormality in asthma. J Allergy 42:203, 1968
180. Tarlo S, Broder I, Spence I: A prospective study of respiratory infection in adult asthmatics and their normal spouses. Clin Allergy 9:293–301, 1979
181. Thurn JR, Crossley K, Gerds A: Bacterial colonization of nursing home residents on admission to an acute care hospital. J Hosp Infect 32:127–133, 1996
182. Tipirneni P, Moore BS, Hyde JS, et al: IgE antibodies to mycoplasma pneumoniae in asthma and other atopic diseases. Ann Allergy 45:1–7, 1980
183. Verespej MA, (ed): Wash, wash. Industry Week 246:23, 1997
184. Viladrich PF, Cabellos C, Pallares R, et al: High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad spectrum cephalosporins. Antimicrob Agents Chemother 40:218–220, 1994
185. Wald TG, Shult P, Krause P, et al: A rhinovirus outbreak among residents of a long-term care facility. Ann Intern Med 123:588–593, 1995
186. Walker RC, Wright AJ: The fluoroquinolones. Mayo Clin Proc 66:1249–1259, 1991
187. Wardlaw A, Geddes DM: Allergic bronchopulmonary aspergillosis: A review. J Royal Soc Med 85:747–751, 1992
188. Washing hands fights colds. Parents Magazine 71:50, 1996
189. Weingarten SR, Riedinger MS, Varis G, et al: Identification of low-risk hospitalized patients with pneumonia: Implications for early conversion to oral antimicrobial therapy. Chest 105:1109–1115, 1994
190. Weismann K, Jakobsen JP, Weismann JE, et al: Zinc gluconate lozenges for common cold: A double-blind clinical trial. Dan Med Bull 37:279–281, 1990
191. Welch MJ: Inhaled steroids and severe viral infection. J Asthma 31:43–50, 1994
192. Welliver RC, Wong DT, Sun M, et al: The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 305:841–846, 1981
193. Whimbey E, Champlin RE, Couch RB, et al: Community respiratory viral infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 22:778–782, 1996
194. Wiggins RE Jr: Invasive aspergillosis. A complication of treatment of temporal arteritis. J Neuroophthalmol 15:36–38, 1995
195. Zaia JA: Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin Infect Dis 17(suppl 2):392–399, 1993
196. Ziment I: Management of respiratory problems in the aged. J Am Geriatr Soc 30(suppl 11):36–44, 1982

Address reprint requests to
Richard E. Bryant, MD
Department of Medicine, L-457
Oregon Health Sciences University
3181 SW Sam Jackson Park Road
Portland, OR 97201